• TScan Therapeutics set a cash-and-equity compensation package for CEO Gavin MacBeath, Chief Legal and Strategy Officer Zoran Zdraveski.
• Cash awards total $822,000 for MacBeath, $416,000 for Zdraveski; first-half payments split between November 2026, February 2027.
• Second-half cash payments hinge on milestones tied to advancing the in vivo solid tumor program.
• Equity awards call for 2,400,000 RSUs for MacBeath, 1,050,000 RSUs for Zdraveski under the 2021 plan.
• One-third of RSUs vest on a financing milestone; remaining two-thirds vest on the first two anniversaries, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-388631), on September 11, 2026, and is solely responsible for the information contained therein.